GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » Revenue

Cambium Bio (ASX:CMB) Revenue : A$0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio Revenue?

Cambium Bio's revenue for the six months ended in Dec. 2024 was A$0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.00 Mil. Cambium Bio's Revenue per Share for the six months ended in Dec. 2024 was A$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was A$0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


Cambium Bio Revenue Historical Data

The historical data trend for Cambium Bio's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio Revenue Chart

Cambium Bio Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cambium Bio Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cambium Bio's Revenue

For the Biotechnology subindustry, Cambium Bio's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cambium Bio's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's Revenue distribution charts can be found below:

* The bar in red indicates where Cambium Bio's Revenue falls into.


;
;

Cambium Bio Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cambium Bio  (ASX:CMB) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Cambium Bio Revenue Related Terms

Thank you for viewing the detailed overview of Cambium Bio's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cambium Bio Business Description

Traded in Other Exchanges
N/A
Address
16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate Elate Ocular is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.

Cambium Bio Headlines

No Headlines